Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for SAR446523, an ...

A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.

Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...

HealthDay News — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets multiple myeloma ...

Medically reviewed by Gagandeep Brar, MD The first sign of multiple myeloma differs for each person with the disease. Since this blood cancer tends to progress silently and slowly, many people do not ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple ...

G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in ...

The Blenrep results presented Monday are from a Phase 3 test, DREAMM-7, that enrolled nearly 500 patients whose multiple myeloma relapsed or was refractory to at least one earlier line of therapy ...

Most people with multiple myeloma are diagnosed in their 60s, 70s or 80s. “Myeloma is predominantly a disease of aging, so the older you get, the more likely you are to get it,” Mohyuddin said.